BlackRock Institutional Trust’s Bellerophon Therapeutics, Inc. BLPH Stock Holding History

BlackRock Institutional Trust’s Portfolio BLPH Stock Details BLPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-1,892	Closed	-$50K	–	3926
2016 Q2	$50K	Hold	1,892	–	–	﹤0.01%	3770
2016 Q1	$70K	Hold	1,892	–	–	﹤0.01%	3758
2015 Q4	$84K	Sell	1,892 -885	-32%	-$42.9K	﹤0.01%	3766
2015 Q3	$216K	Hold	2,777	–	–	﹤0.01%	3633
2015 Q2	$330K	Buy	2,777 +1,873	+207%	+$255K	﹤0.01%	3569
2015 Q1	$125K	Buy	+904	New	+$141K	﹤0.01%	3682

Other funds holding BLPH

NMVA

New Mountain Vantage Advisers New York $4.33B AUM 35.3% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

VKH

Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return

Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Geneva Advisors Chicago, Illinois $5.81B AUM 23.71% 1-Year Est. Return

BlackRock Institutional Trust's BLPH Position: Q3 2016 in Review

BlackRock Institutional Trust sold out of Bellerophon Therapeutics, Inc. (BLPH) in Q3 2016, closing a stake of 1,892 shares — an estimated $50K sold.

BlackRock Institutional Trust first reported a position in BLPH in Q1 2015 and held it in 6 quarters. The position peaked at $330K in Q2 2015. 15 funds tracked by Wall St. Rank hold BLPH as of Q3 2016.

BlackRock Institutional Trust reported no remaining Bellerophon Therapeutics, Inc. position as of Q3 2016 after selling out during the quarter.
BlackRock Institutional Trust sold 1,892 Bellerophon Therapeutics, Inc. shares in Q3 2016, an estimated $50K.
BlackRock Institutional Trust first reported a position in Bellerophon Therapeutics, Inc. in Q1 2015 and held it in 6 quarters.
BlackRock Institutional Trust's Bellerophon Therapeutics, Inc. position peaked at $330K in Q2 2015.
15 funds tracked by Wall St. Rank held Bellerophon Therapeutics, Inc. as of Q3 2016.

Based on BlackRock Institutional Trust's 13F filing for Q3 2016, filed 8 Nov 2016.